ClinicalTrials.gg
RecruitingNCT07298642Updated Dec 23, 2025

Extended-field Proton Therapy for Cervical Cancer

A Phase 2/3 interventional study of Proton extended field radiation therapy and Photon extended field radiation therapy in Cervical Cancer, sponsored by National Taiwan University Hospital. Recruiting at 2 sites in Taiwan. Open to female participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by National Taiwan University Hospital · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
20 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Uterine Cervical Neoplasms by National Taiwan University Hospital — 2 open to participants now, 2 under way, 1 of them phase 3. Uterine Cervical Neoplasms · National Taiwan University Hospital.

Started
2025
the only one that year
Phase 2/3
Only one
of the 15
Registered
15th of 15
by date

Among the 15 studies in Uterine Cervical Neoplasms by National Taiwan University Hospital, this one is the only one that started in 2025, is the only one in phase 2/3, and was the 15th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

2 of the 15 studies in Uterine Cervical Neoplasms by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 20 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Uterine Cervical Neoplasms by National Taiwan University Hospital, or all of them as a file.
02

Study summary

Severe lymphopenia is a common complication of extended-field radiotherapy in cervical cancer, significantly impacting immune function and clinical outcomes. This study aims to evaluate whether proton therapy, with its superior dose distribution, can reduce lymphopenia and improve survival and toxicity profiles compared to photon therapy.

Read the detailed description

This study is a prospective, observational cohort study designed to evaluate the effects of proton therapy and photon therapy in patients with stage IIIC1 or IIIC2 cervical cancer undergoing extended-field radiotherapy. Primary data collection will include clinical outcomes, radiotherapy-related toxicities, lymphocyte counts, and immune cell subsets (e.g., CD4, CD8, CD19, and CD16+56), measured at baseline, during treatment, and post-treatment. Secondary data collection will involve tissue banking for future translational research projects, including serum, plasma, and whole blood for DNA analysis.

The study will be conducted in two tertiary cancer centers (CGMH and NTUCC), with individual patient participation proton or photon treatment approximately 9 weeks, followed by an additional five years for long-term follow-up to assess survival outcomes and late toxicities. This design enables robust comparison of the therapeutic impact of proton and photon therapies on clinical and immunological endpoints, providing evidence to guide personalized treatment decisions in cervical cancer.

03

Conditions studied

  • Cervical Cancer

Keywords

  • cervical cancer
  • proton therapy
  • extended field
04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed cervical cancer, stage ≥ IIIC.
  • Age between 20 and 85 years.
  • (ECOG) performance status of 0-1.
  • Eligible for extended-field radiotherapy as determined by the treating physician.
  • Induction chemotherapy with paclitaxel and carboplatin is allowed if the duration is ≤ 6 weeks or ≤ 2 cycles.
  • RT alone, or concurrent single-agent chemotherapy with weekly cisplatin or carboplatin during radiation therapy is allowed, while the use of any other concurrent antineoplastic agents is prohibited.
  • Consolidative chemotherapy or immunotherapy after radiation therapy is allowed.

Exclusion criteria

Exclusion Criteria:

  • Prior history of pelvic or abdominal radiotherapy.
  • Presence of distant or other active within the past 5 years, excluding non-melanoma skin cancer.
  • Severe comorbid conditions, such as uncontrolled diabetes, cardiovascular disease, or disorders, that may interfere with treatment or study participation.
  • Pregnancy or breastfeeding at the time of enrollment.
  • Psychiatric or social conditions that would limit compliance with study requirements or follow-up.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Proton extended-field radiotherapy

    Proton extended-field radiotherapy

    Radiation: Proton extended field radiation therapy

  • Active comparator
    Photon extended-field radiotherapy

    Photon extended-field radiotherapy

    Radiation: Photon extended field radiation therapy

Interventions

  • RadiationProton extended field radiation therapy

    Proton extended field radiation therapy

  • RadiationPhoton extended field radiation therapy

    Photon extended field radiation therapy

06

What researchers measure

Primary outcomes

  1. Lymphocyte Counts

    Lymphocyte Counts: The absolute lymphocyte count will be measured pre-treatment, during treatment, and post-treatment. Severe lymphopenia is defined as an absolute lymphocyte count \<500/μL

    Time frame: Baseline; Weeks 3-5 of radiotherapy; 2 weeks after radiotherapy completion

  2. Immune Cell Subsets

    Immune Cell Subsets: The percentage of CD4 (%), CD8 (%), CD19 (%), and CD16+56 (%) will be monitored to assess the immune response to therapy

    Time frame: Baseline; Weeks 3-5 of radiotherapy; 2 weeks after radiotherapy completion

Secondary outcomes

  1. Radiotherapy-Related Toxicities

    \* Radiotherapy-Related Toxicities: Toxicity levels will be assessed using the CTCAE grading system. Acute and late toxicities will be documented, with a focus on gastrointestinal, hematological, genitourinary, and skin toxicities as part of the comparison between proton and photon therapy.

    Time frame: Follow-up for five years

  2. Survival outcomes

    * Overall Survival (OS): The time from the start of treatment to death from any cause. * Progression-Free Survival (PFS): The time from the start of treatment to disease progression or death, whichever occurs first. PFS provides insight into the therapeutic efficacy and disease control achieved by each treatment modality.

    Time frame: Follow-up for five years

07

Study locations

2 of 2 sites recruiting
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
    Recruiting
    • Jenny Ling-Yu Chen Attending Physician, MD PhD · Contactntuhrec@ntuh.gov.tw · 886-2-23123456
    • Jenny Ling-Yu Chen, MD PhD · Principal investigator
    • Che-Yu Hsu, MD PhD · Sub investigator
  • Chang Gung Memorial Hospital
    Taoyuan, Taiwan
    Recruiting
    • Chun-Chieh Wang Attending Physician, MD PhD · Contactisc@cgmh.org.tw · 886-3-3281200
    • Chun-Chieh Wang, MD PhD · Principal investigator
    • Po-Jui Chen, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for May 2030, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2025
First posted
Dec 23, 2025
StartActual
Sep 30, 2025
Primary completionEst.
May 2030
CompletionEst.
May 2030
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07298642
Responsible party
National Taiwan University Clinical Trial Center (Clinical Associate Professor, Attending Physician, Jenny Ling-Yu Chen MD PhD, National Taiwan University Hospital) — Principal investigator
First posted
Dec 23, 2025
Start date
Sep 30, 2025
Primary completion
May 2030 (estimated)
Completion
May 2030 (estimated)
Last update
Dec 23, 2025

Study contacts

Jenny Ling-Yu Chen Attending Physician, MD PhD
Contact
ntuhrec@ntuh.gov.tw
886-2-23123456 ext. 262643

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion